At the same time, multiple blockbuster GLP-1 therapies are already on the market (Ozempic, Wegovy, and Mounjaro), with numerous next-generation analogues and combination incretin therapies currently in development
No controlled KLOW trial has tested this schedule or established when skin changes should appear
Al-Ozairi E et al
1 OCDEM, University of Oxford, Oxford, UK, 2 NIHR Oxford Biomedical Research Centre, Oxford, UK, 3 Department of Psychiatry, University of Oxford, Oxford, UK, 4 Centre for Human Genetics, University of Oxford, Oxford, UK, 5 Oxford Drug Discovery Institute, University of Oxford, Oxford, UK, 6 University of Coimbra, Coimbra, Portugal, 7 University of Gothenburg, Gothenburg, Sweden, 8 Nuffield Department of Population Health, University of Oxford, Oxford, UK
Top panel: The ratio of oxidized and reduced glutathione ratio were reduced by 18-20% in the high-dose group (striped bars) at weeks 1 and 2